These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34528053)

  • 1. An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
    Yan Y; Huang C; Shu Y; Wen H; Shan C; Wang X; Liu J; Li W
    Org Biomol Chem; 2021 Oct; 19(38):8352-8366. PubMed ID: 34528053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices.
    Huang C; Shu Y; Zhu Y; Liu H; Wang X; Wen H; Liu J; Li W
    Bioorg Med Chem; 2022 Aug; 68():116821. PubMed ID: 35661851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051.
    Long K; Close DA; Johnston PA; Huryn DM
    Bioorg Med Chem Lett; 2024 Aug; 108():129810. PubMed ID: 38782078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
    Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
    ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8.
    Xiao Y; Awasthee N; Liu Y; Meng C; He MY; Hale S; Karki R; Lin Z; Mosterio M; Garcia BA; Kridel R; Liao D; Zheng G
    J Med Chem; 2024 Aug; 67(15):12784-12806. PubMed ID: 38949959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
    Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
    J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
    Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells.
    Kim JY; Han SY; Yoo J; Kim GW; Jeon YH; Lee SW; Park J; Kwon SH
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
    Balasubramanian S; Ramos J; Luo W; Sirisawad M; Verner E; Buggy JJ
    Leukemia; 2008 May; 22(5):1026-34. PubMed ID: 18256683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8.
    Kulandaivelu U; Chilakamari LM; Jadav SS; Rao TR; Jayaveera KN; Shireesha B; Hauser AT; Senger J; Marek M; Romier C; Jung M; Jayaprakash V
    Bioorg Chem; 2014 Dec; 57():116-120. PubMed ID: 25462986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning.
    Nurani A; Yamashita Y; Taki Y; Takada Y; Itoh Y; Suzuki T
    Chem Pharm Bull (Tokyo); 2024; 72(2):173-178. PubMed ID: 38296560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.